ZA202004317B - Immunostimulatory compositions - Google Patents
Immunostimulatory compositionsInfo
- Publication number
- ZA202004317B ZA202004317B ZA2020/04317A ZA202004317A ZA202004317B ZA 202004317 B ZA202004317 B ZA 202004317B ZA 2020/04317 A ZA2020/04317 A ZA 2020/04317A ZA 202004317 A ZA202004317 A ZA 202004317A ZA 202004317 B ZA202004317 B ZA 202004317B
- Authority
- ZA
- South Africa
- Prior art keywords
- immunostimulatory compositions
- immunostimulatory
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17207746 | 2017-12-15 | ||
| EP17207750 | 2017-12-15 | ||
| EP17207740 | 2017-12-15 | ||
| PCT/EP2018/083956 WO2019115385A1 (en) | 2017-12-15 | 2018-12-07 | Immunostimulatory compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202004317B true ZA202004317B (en) | 2023-05-31 |
Family
ID=66818991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/04317A ZA202004317B (en) | 2017-12-15 | 2020-07-14 | Immunostimulatory compositions |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US11542507B2 (en) |
| EP (3) | EP3700564A1 (en) |
| JP (5) | JP2021506246A (en) |
| KR (3) | KR20200099556A (en) |
| CN (3) | CN111447949A (en) |
| AU (3) | AU2018385257A1 (en) |
| BR (3) | BR112020011845A2 (en) |
| CA (3) | CA3085575A1 (en) |
| CL (3) | CL2020001561A1 (en) |
| CO (3) | CO2020007102A2 (en) |
| CR (1) | CR20200260A (en) |
| DO (3) | DOP2020000113A (en) |
| IL (3) | IL274975A (en) |
| MX (3) | MX2020006246A (en) |
| PE (2) | PE20210636A1 (en) |
| PH (3) | PH12020550903A1 (en) |
| SG (3) | SG11202004952UA (en) |
| TW (3) | TW201936924A (en) |
| UY (3) | UY38016A (en) |
| WO (3) | WO2019115385A1 (en) |
| ZA (1) | ZA202004317B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3145889A1 (en) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| CN113493790A (en) * | 2020-04-01 | 2021-10-12 | 南京华普生物技术股份有限公司 | CpG ODN with immunoregulation function and application thereof |
| WO2022032191A1 (en) | 2020-08-07 | 2022-02-10 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| CN112159814B (en) * | 2020-10-29 | 2023-05-16 | 中国农业科学院兰州兽医研究所 | CpG oligodeoxynucleotide, preparation and use thereof |
| CN113797329A (en) * | 2021-10-19 | 2021-12-17 | 启锰生物科技(江苏)有限公司 | Vaccine adjuvant composition of bivalent manganese adjuvant and CpG adjuvant and preparation method thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719028A (en) * | 1992-12-07 | 1998-02-17 | Third Wave Technologies Inc. | Cleavase fragment length polymorphism |
| CA2194761C (en) * | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| AP1775A (en) * | 1999-09-25 | 2007-08-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
| MXPA02003059A (en) * | 1999-09-27 | 2002-09-30 | Univ Iowa Res Found | Methods related to immunostimulatory nucleic acid induced interferon. |
| KR100359753B1 (en) * | 1999-12-21 | 2002-11-09 | 주식회사 제넥신 | Modified phosphodiester CpG oligdeoxynucleotides conjugated with a dG run which have improved immunomodulatory activity and safety |
| AR040996A1 (en) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
| KR101137572B1 (en) * | 2003-06-11 | 2012-05-30 | 이데라 파마슈티칼즈, 인코포레이티드 | Stabilized immunomodulatory oligonucleotides |
| AU2004275876B2 (en) | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
| CN101454451A (en) * | 2003-10-30 | 2009-06-10 | 科勒制药有限公司 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
| CA2543072A1 (en) * | 2003-11-05 | 2005-06-02 | Pevion Biotech Ltd. | Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens |
| KR100558851B1 (en) * | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | Modified CpG oligodeoxynucleotide with improved immunoregulatory function |
| US8895521B2 (en) * | 2004-05-06 | 2014-11-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for the treatment of uveitis |
| JP2008531018A (en) * | 2005-02-24 | 2008-08-14 | コーリー ファーマシューティカル グループ，インコーポレイテッド | Immunostimulatory oligonucleotide |
| EP1764108A1 (en) * | 2005-09-14 | 2007-03-21 | Gunther Hartmann | Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides |
| EP1991678B2 (en) | 2006-02-15 | 2020-07-15 | Rechtsanwalt Thomas Beck | Compositions and methods for oligonucleotide formulations |
| CN100418583C (en) | 2006-02-21 | 2008-09-17 | 朱鸿飞 | Medicine composition for preventing and treating mammitis |
| US20080124366A1 (en) | 2006-08-06 | 2008-05-29 | Ohlfest John R | Methods and Compositions for Treating Tumors |
| CN102851295B (en) * | 2006-08-28 | 2015-01-07 | 长春华普生物技术有限公司 | Toll-like receptor regulatory oligonucleotide and application thereof |
| MX2009003398A (en) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity. |
| NZ582972A (en) * | 2007-08-13 | 2011-09-30 | Coley Pharm Gmbh | Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles |
| WO2010129672A1 (en) | 2009-05-05 | 2010-11-11 | Miragen Therapeutics | Lipophilic polynucleotide conjugates |
| AU2010246652B2 (en) | 2009-05-14 | 2014-10-02 | Bayer Intellectual Property Gmbh | Enhanced immune response in avian species |
| AU2011259718B2 (en) * | 2010-05-28 | 2016-03-03 | Zoetis Belgium S.A. | Vaccines comprising cholesterol and CpG as sole adjuvant - carrier molecules |
| UA118537C2 (en) | 2010-12-22 | 2019-02-11 | Байєр Інтеллектуал Проперті Гмбх | Enhanced immune response in bovine species |
| EP2471926A3 (en) * | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
| TR201808393T4 (en) * | 2011-05-26 | 2018-07-23 | Intervet Int Bv | Immunostimulatory oligodeoxynucleotides. |
| JP5872684B2 (en) * | 2011-05-26 | 2016-03-01 | インターベット インターナショナル ベー． フェー． | Immunostimulatory oligodeoxynucleotides |
| EP3563872A1 (en) | 2012-04-05 | 2019-11-06 | Massachusetts Institute Of Technology | Immunostimulatory compositions and methods of use thereof |
| AR091569A1 (en) | 2012-06-28 | 2015-02-11 | Intervet Int Bv | TOLL TYPE RECEIVERS |
| US20150301058A1 (en) * | 2012-11-26 | 2015-10-22 | Caris Science, Inc. | Biomarker compositions and methods |
| CA2909868C (en) | 2013-05-01 | 2021-10-19 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
| CN112263675B (en) * | 2013-07-19 | 2024-02-27 | 财团法人卫生研究院 | CpG oligodeoxynucleotides, immune compositions comprising same and methods of preparing compositions and stimulating immune responses by same |
| AR097029A1 (en) * | 2013-07-26 | 2016-02-17 | Intervet Int Bv | ACCELERATION OF THE IMMUNE RESPONSE INDUCED BY VECTOR VIRUS IN BIRDS, COMPOSITION, USE, VACCINATION METHOD AND METHOD FOR ACCELERATING THE IMMUNE RESPONSE |
| GB2517700A (en) * | 2013-08-27 | 2015-03-04 | Lgc Ltd | Oligonucleotides comprising a secondary structure and uses thereof |
| US10155950B2 (en) * | 2014-02-28 | 2018-12-18 | Bayer Animal Health Gmbh | Immunostimulatory plasmids |
| WO2017139570A1 (en) | 2016-02-12 | 2017-08-17 | Massachusetts Intitute Of Technology | Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne |
-
2018
- 2018-12-07 JP JP2020531982A patent/JP2021506246A/en active Pending
- 2018-12-07 JP JP2020531972A patent/JP7273040B2/en active Active
- 2018-12-07 SG SG11202004952UA patent/SG11202004952UA/en unknown
- 2018-12-07 CN CN201880080814.7A patent/CN111447949A/en active Pending
- 2018-12-07 KR KR1020207020350A patent/KR20200099556A/en not_active Application Discontinuation
- 2018-12-07 PE PE2020000766A patent/PE20210636A1/en unknown
- 2018-12-07 US US16/772,046 patent/US11542507B2/en active Active
- 2018-12-07 KR KR1020207020349A patent/KR20200098637A/en not_active Application Discontinuation
- 2018-12-07 MX MX2020006246A patent/MX2020006246A/en unknown
- 2018-12-07 WO PCT/EP2018/083956 patent/WO2019115385A1/en unknown
- 2018-12-07 MX MX2020006244A patent/MX2020006244A/en unknown
- 2018-12-07 EP EP18829225.4A patent/EP3700564A1/en active Pending
- 2018-12-07 AU AU2018385257A patent/AU2018385257A1/en active Pending
- 2018-12-07 EP EP18811581.0A patent/EP3701032A1/en active Pending
- 2018-12-07 CA CA3085575A patent/CA3085575A1/en active Pending
- 2018-12-07 BR BR112020011845-1A patent/BR112020011845A2/en unknown
- 2018-12-07 AU AU2018382419A patent/AU2018382419A1/en active Pending
- 2018-12-07 AU AU2018385256A patent/AU2018385256A1/en active Pending
- 2018-12-07 WO PCT/EP2018/083958 patent/WO2019115386A1/en unknown
- 2018-12-07 CA CA3085657A patent/CA3085657A1/en active Pending
- 2018-12-07 BR BR112020011815-0A patent/BR112020011815A2/en unknown
- 2018-12-07 WO PCT/EP2018/084019 patent/WO2019115402A1/en unknown
- 2018-12-07 JP JP2020531988A patent/JP7458977B2/en active Active
- 2018-12-07 US US16/771,789 patent/US20210062192A1/en not_active Abandoned
- 2018-12-07 MX MX2020006243A patent/MX2020006243A/en unknown
- 2018-12-07 CN CN201880089469.3A patent/CN111801419A/en active Pending
- 2018-12-07 PE PE2020000765A patent/PE20210635A1/en unknown
- 2018-12-07 BR BR112020011838-9A patent/BR112020011838A2/en unknown
- 2018-12-07 CA CA3085661A patent/CA3085661A1/en active Pending
- 2018-12-07 EP EP18829227.0A patent/EP3694549A1/en active Pending
- 2018-12-07 US US16/772,541 patent/US11932857B2/en active Active
- 2018-12-07 CN CN201880089491.8A patent/CN111801116A/en active Pending
- 2018-12-07 SG SG11202004471RA patent/SG11202004471RA/en unknown
- 2018-12-07 SG SG11202004773SA patent/SG11202004773SA/en unknown
- 2018-12-07 KR KR1020207020351A patent/KR20200098638A/en not_active Application Discontinuation
- 2018-12-07 CR CR20200260A patent/CR20200260A/en unknown
- 2018-12-13 TW TW107144948A patent/TW201936924A/en unknown
- 2018-12-13 TW TW107144947A patent/TWI821224B/en active
- 2018-12-13 TW TW107144946A patent/TW201940192A/en unknown
- 2018-12-14 UY UY0001038016A patent/UY38016A/en not_active Application Discontinuation
- 2018-12-14 UY UY0001038014A patent/UY38014A/en not_active Application Discontinuation
- 2018-12-14 UY UY0001038015A patent/UY38015A/en not_active Application Discontinuation
-
2020
- 2020-05-27 IL IL274975A patent/IL274975A/en unknown
- 2020-06-03 IL IL275086A patent/IL275086A/en unknown
- 2020-06-08 IL IL275217A patent/IL275217A/en unknown
- 2020-06-10 DO DO2020000113A patent/DOP2020000113A/en unknown
- 2020-06-10 DO DO2020000106A patent/DOP2020000106A/en unknown
- 2020-06-10 DO DO2020000107A patent/DOP2020000107A/en unknown
- 2020-06-11 CL CL2020001561A patent/CL2020001561A1/en unknown
- 2020-06-11 CO CONC2020/0007102A patent/CO2020007102A2/en unknown
- 2020-06-11 CO CONC2020/0007120A patent/CO2020007120A2/en unknown
- 2020-06-11 CL CL2020001562A patent/CL2020001562A1/en unknown
- 2020-06-11 CL CL2020001560A patent/CL2020001560A1/en unknown
- 2020-06-11 CO CONC2020/0007100A patent/CO2020007100A2/en unknown
- 2020-06-15 PH PH12020550903A patent/PH12020550903A1/en unknown
- 2020-06-15 PH PH12020550906A patent/PH12020550906A1/en unknown
- 2020-06-15 PH PH12020550904A patent/PH12020550904A1/en unknown
- 2020-07-14 ZA ZA2020/04317A patent/ZA202004317B/en unknown
-
2022
- 2022-08-08 US US17/883,031 patent/US20230174990A1/en active Pending
- 2022-11-18 US US18/057,053 patent/US20230332162A1/en active Pending
-
2023
- 2023-08-07 JP JP2023128316A patent/JP2023153970A/en active Pending
- 2023-08-07 US US18/366,306 patent/US20240076681A1/en active Pending
- 2023-08-21 JP JP2023134080A patent/JP2023156485A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3665237T3 (en) | Compositions | |
| ZA201905792B (en) | Hair-treatment compositions | |
| GB201811312D0 (en) | Compositions | |
| GB202015955D0 (en) | Compositions | |
| GB2600652B (en) | Novel compositions | |
| ZA202004317B (en) | Immunostimulatory compositions | |
| GB201719480D0 (en) | Compositions | |
| GB201911609D0 (en) | Compositions | |
| GB201707909D0 (en) | Compositions | |
| IL259575B (en) | Immunostimulatory compositions | |
| GB201707454D0 (en) | Compositions | |
| PL3609464T3 (en) | Xanthohumol-based compositions | |
| GB201803923D0 (en) | Compositions | |
| GB2562241B (en) | Vaccine compositions | |
| IL271603A (en) | Immunogenic compositions | |
| GB201717712D0 (en) | Compositions | |
| GB2570649B (en) | Compositions | |
| GB201718251D0 (en) | Vaccine Compositions | |
| GB201805676D0 (en) | Compositions | |
| IL269120A (en) | Compositions comprising avelumab | |
| GB2564901B (en) | Vaccine compositions | |
| GB201719085D0 (en) | Novel Compositions | |
| GB201719083D0 (en) | Novel compositions | |
| GB201713226D0 (en) | Compositions | |
| GB201710068D0 (en) | Compositions |